Evotec SE (EVO) Non Operating Income (2009 - 2025)
Evotec SE (EVO) reported Non Operating Income of $1802.7 for Q3 2025, up 108.05% on a YoY basis from $866.45 in Q3 2024, and up 108.05% sequentially from -$22382.8 in Q3 2024.
Evotec SE (EVO) Non Operating Income (2009 - 2025) Analysis & Trends
Evotec SE (EVO) has 9 years of Non Operating Income data on file, last reported at $1802.7 in Q3 2025.
- For the quarter ending Q3 2025, Non Operating Income rose 108.05% year-over-year to $1802.7; the trailing twelve-month figure through Sep 2025 stood at -$178.5 million (changed 0.02% YoY), and the FY2022 full-year result was -$178.3 million, down 179.55% from the prior year.
- Non Operating Income climbed to $1802.7 in Q3 2025, from -$22382.8 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $223.9 million in Q4 2021 to a low of -$178.5 million in Q4 2022.
- A 5-year average of $4.2 million and a median of $19299.6 in 2023 frame the typical range for Non Operating Income.
- Across the five-year window, Non Operating Income soared 41923.99% in 2021 and plunged 235.08% in 2022, its largest moves.
- Tracing EVO's Non Operating Income over 5 years: stood at $223.9 million in 2021, then tumbled by 179.7% to -$178.5 million in 2022, then soared by 100.01% to $19299.6 in 2023, then slumped by 215.98% to -$22382.8 in 2024, then jumped by 108.05% to $1802.7 in 2025.
- Business Quant data shows EVO's Non Operating Income at $1802.7 in Q3 2025, -$22382.8 in Q3 2024, and $19299.6 in Q3 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -216.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 20.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -7.50 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 53.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Evotec SE | 351.60 Mn | 351.08 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 1,802.68 |
| Sep 30, 2024 | -22,382.81 |
| Sep 30, 2023 | 19,299.62 |
| Dec 31, 2022 | -178.47 Mn |
| Sep 30, 2022 | 30,081.86 |
| Jun 30, 2022 | -21,945.09 |
| Mar 31, 2022 | -77,661.28 |
| Dec 31, 2021 | 223.94 Mn |
| Sep 30, 2021 | 144,643.13 |
| Jun 30, 2021 | 70,387.26 |
| Mar 31, 2021 | 57,491.63 |
| Dec 31, 2020 | 532,882.03 |
| Sep 30, 2020 | -10,333.98 |
| Dec 31, 2019 | -6.68 Mn |
| Sep 30, 2010 | 242.76 |
| Jun 30, 2010 | 67.57 |
| Mar 31, 2010 | 160.63 |
| Dec 31, 2009 | -3.72 Mn |
| Jun 30, 2009 | 369.01 |
| Mar 31, 2009 | -2.07 |